DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.
The trial of the SGLT2 inhibitor dapagliflozin (Farxiga) was conducted in more than 6,000 patients with HF with mildly reduced or preserved EF, defined as left ventricular EF greater than 40%. Approximately half of all patients with HF have mildly reduced or preserved EF, with few therapeutic options available.
“We are delighted to have met the primary

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.
The trial of the SGLT2 inhibitor dapagliflozin (Farxiga) was conducted in more than 6,000 patients with HF with mildly reduced or preserved EF, defined as left ventricular EF greater than 40%. Approximately half of all patients with HF have mildly reduced or preserved EF, with few therapeutic options available.
“We are delighted to have met the primary